文献速递中医内科中药与中成药合理使用

白术挥发油与人参总皂苷经MAMs调控缓解化疗性腹泻机制

Mechanism of Shenzhu components in alleviating chemotherapy-induced diarrhea via mitochondria-associated endoplasmic reticulum membranes (MAMs) regulation.
PubMed 文献 · J Ethnopharmacol · 2025-11-27

该研究以5-FU诱导的化疗性腹泻(CID)小鼠模型为对象,探讨白术挥发油(AMO)与人参总皂苷(PGS)组合(AP)通过调控线粒体相关内质网膜(MAMs)恢复肠道屏障功能的机制。结果显示AP可减轻腹泻与体重下降、修复结肠病理损伤,并经cGMP-PKG通路抑制IP3R介导的钙释放、下调MAMs钙通道复合物,从而改善线粒体功能与内质网应激、减少凋亡并上调紧密连接蛋白。

要点

  • AP可缓解5-FU诱导的小鼠CID症状与结肠损伤。
  • AP经cGMP-PKG通路调控MAMs钙转运与结构。
  • AP上调紧密连接蛋白并调节Bcl-2/Bax抑制凋亡。

核心结论

  • 5-FU通过破坏MAMs结构与功能导致肠道屏障损伤,AP经cGMP-PKG-MAMs轴纠正钙失衡与接触异常,多维度缓解CID。

研究设计与样本

  • 采用5-FU诱导的CID小鼠模型,评估AP对腹泻评分与体重的影响。
  • 以HE染色观察结肠病理,透射电镜观察MAMs、内质网与线粒体超微结构。
  • 用免疫组化检测CHOP与GRP78,生化法评估线粒体膜电位、ROS与ATP,TUNEL法测细胞凋亡。
  • 结合RNA-seq与生物信息学分析机制,并用ELISA、Western blotting与免疫荧光验证相关蛋白。

主要发现

  • AP显著缓解5-FU诱导的小鼠体重下降、腹泻与结肠病理损伤,并恢复肠道屏障通透性标志物。
  • 电镜显示AP逆转5-FU所致的线粒体肿胀、嵴丢失及内质网扩张与碎片化。
  • 5-FU破坏MAMs稳态,AP通过下调Mfn2表达恢复MAMs正常结构。
  • RNA-seq提示AP协调调控线粒体功能与内质网稳态等多因素,cGMP-PKG通路激活被鉴定为核心治疗机制并经WB验证。
  • AP激活cGMP-PKG通路抑制IP3R介导的内质网钙释放并下调MAMs钙通道复合物(IP3R-GRP75-VDAC1-MCU),改善线粒体功能障碍与内质网应激、减少线粒体钙超载。

临床怎么用

  • 对5-FU化疗相关腹泻,可关注白术与人参配伍(AMO+PGS)补气健脾改善胃肠功能的传统应用。
  • MAMs可作为CID的潜在治疗靶点,用于解释中药复方调控细胞器相互作用的优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Chemotherapy-induced diarrhea (CID) is a common side effect of 5-fluorouracil (5-FU). Traditional Chinese medicine (TCM) is responsible for the core pathogenesis of spleen qi deficiencies. Therefore, the herbal pair of the rhizomes of Atractylodes macrocephala Koidz. (AM) and the roots of Panax ginseng C. A. Mey. (PG) known for its effects on tonifying qi and strengthening the spleen, has been traditionally used to improve gastrointestinal function. AIM OF THE STUDY: This study aimed to elucidate how the combination of Atractylodis Macrocephalae volatile oil (AMO) and Panax ginseng total saponins (PGS) (AP) regulated mitochondria-associated endoplasmic reticulum membranes (MAMs) to restore intestinal barrier function in CID. METHODS: A 5-FU-induced CID mouse model was used to evaluate the effects of AP on diarrhea scores and body weight. Hematoxylin-eosin (HE) staining was used to examine colon pathological changes. Transmission electron microscopy (TEM) was used to observe MAMs, endoplasmic reticulum (ER), and mitochondrial ultrastructure. Immunohistochemistry was performed to detect ER stress markers (CHOP and GRP78) and biochemical assays were used to assess mitochondrial function (membrane potential, ROS, and ATP). The TUNEL assay was conducted to measure cell apoptosis. RNA sequencing (RNA-seq) and bioinformatics analysis were combined to explore the underlying mechanisms, followed by validation of related proteins (cGMP, PKG, IP3R, GRP75, VDAC1, MCU, Mfn2, ZO-1, Occludin, Bcl-2 and Bax) using ELISA, Western blotting(WB), and immunofluorescence. RESULTS: AP significantly alleviated 5-FU-induced body weight loss, diarrhea, and colonic pathological damage in mice, while restoring intestinal barrier permeability markers. TEM revealed that AP reversed 5-FU-induced mitochondrial swelling, cristae loss, and ER dilation and fragmentation. Further studies demonstrated that 5-FU disrupted MAMs homeostasis, whereas AP restored the normal MAMs structure by downregulating Mfn2 expression. At the mechanistic level, RNA-seq analysis demonstrated that AP alleviated CID by coordinating the regulation of multiple factors, including mitochondrial function and endoplasmic reticulum homeostasis, with activation of the cGMP-PKG signaling pathway identified as a central therapeutic mechanism, which was verified by WB. AP activated the cGMP-PKG pathway to suppress IP3R-mediated ER calcium release and downregulated the MAMs calcium channel complex (IP3R-GRP75-VDAC1-MCU), thereby ameliorating mitochondrial dysfunction and ER stress while reducing mitochondrial calcium overload. Ultimately, AP inhibited apoptosis by modulating the Bcl-2/Bax balance and restored intestinal barrier integrity through the upregulation of tight junction proteins. CONCLUSION: This study revealed for the first time that 5-FU induced intestinal barrier damage by disrupting the structure and function of MAMs. In contrast, AP corrected calcium imbalance and contacted abnormality through the cGMP-PKG-MAMs axis, resulting in multidimensional relief of CID. This finding provided a novel therapeutic target (MAMs) for CID and highlighted the unique advantage of Chinese herbal complexes in modulating organelle interactions.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Cao Z, Liu R, Li K, et al. Mechanism of Shenzhu components in alleviating chemotherapy-induced diarrhea via mitochondria-associated endoplasmic reticulum membranes (MAMs) regulation. J Ethnopharmacol. 2025. PMID: 41317807. doi:10.1016/j.jep.2025.120958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。